NiQuitin CQ Smoking Cessation Lozenge Could Be On U.S. Shelves By Year-End
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline has submitted an NDA for its NiQuitin CQ lozenges and could receive FDA approval before the end of the year, the firm said
You may also be interested in...
Nicotine Lozenge Underdosing Discouraged In GSK Smoking Cessation Study
Smokers should be encouraged to use at least seven to eight nicotine lozenges per day when attempting to quit smoking, researchers suggest in the June 10 Archives of Internal Medicine
GSK Consumer Healthcare Trading Profit Boosted 23% By Block Drug
GlaxoSmithKline's Block Drug acquisition drove trading profit for the consumer healthcare business up 23% to $798 mil. in 2001
NiQuitin CQ
GlaxoSmithKline's UK launch of smoking cessation lozenges backed by £10 mil. (approximately $14.2 mil.) marketing campaign including £5 mil. ad campaign beginning in December, firm says. Mint-flavored lozenges contain either 2 mg or 4 mg nicotine polacrilex and launched in UK pharmacies in October. A one-week supply costs roughly $24.80. Launch could pave the way for eventual product introduction in U.S. Study finding lozenges lead to higher success rate than other nicotine-replacement therapies slated for publication in March Archives of Internal Medicine...